Search results for "Rectal Cancer"

showing 10 items of 978 documents

Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer

2022

The role of the tumor microenvironment (TME) in the progression of colorectal cancer (CRC) and its acquisition of resistance to treatment become the research hotspots. As an important component of TME, the tumor-associated macrophages (TAMs) regulate multiple critical oncogenic processes, namely, occurrence, proliferation, metastasis, and drug resistance in CRC. In this review, we have discussed the functional and therapeutic significance of TAMs in CRC. M1 macrophages act as the tumor suppressor while M2 macrophages promote CRC. The polarization of TAMs is mainly regulated by the pathways such as NFKB1 pathways, STAT3 pathways, WNT5A pathways, and PI3K pathways in CRC. Furthermore, the M2 …

Cancer Researchtreatmentstomatognathic systemOncologytumor-associated macrophagesmechanismtumor microenvironmentNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal cancerskin and connective tissue diseasesRC254-282digestive system diseaseshormones hormone substitutes and hormone antagonistsFrontiers in Oncology
researchProduct

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

2022

Background: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studied the frequency and clinical characteristics in a real-world and population-based setting. Methods: Patients from three Nordic population-based cohorts and the real-life RAXO-study were combined. RAS and BRAF tests were performed in routine healthcare, except for one cohort. The dataset consisted of 2,559 patients, of which 1,871 could be accurately classified as KRAS, NRAS, and BRAF-V600E. Demog…

Cancer och onkologireal-worldendocrine system diseasesEGFR3122 CancersKRAS mutationKRAS-G12C mutationKRAS MUTATIONScolorectal cancersuolistosyövät3126 Surgery anesthesiology intensive care radiologyTUMORSdigestive system diseasesetäpesäkkeetmetastaticpopulation-basedPOOLED ANALYSISRAS MUTATIONSsyöpägeenitCancer and Oncologymutaatiotkohorttitutkimusneoplasmspaksusuolisyöpä
researchProduct

MYC dosage compensation is mediated by miRNA-transcription factor interactions in aneuploid cancer

2021

Summary We hypothesize that dosage compensation of critical genes arises from systems-level properties for cancer cells to withstand the negative effects of aneuploidy. We identified several candidate genes in cancer multiomics data and developed a biocomputational platform to construct a mathematical model of their interaction network with micro-RNAs and transcription factors, where the property of dosage compensation emerged for MYC and was dependent on the kinetic parameters of its feedback interactions with three micro-RNAs. These circuits were experimentally validated using a genetic tug-of-war technique to overexpress an exogenous MYC, leading to overexpression of the three microRNAs …

Candidate geneMultidisciplinaryDosage compensationColorectal cancerBioinformaticsScienceQCancerMycBiologymedicine.diseaseArticleDownregulation and upregulationCancer cellmicroRNATranscription factorsmedicineCancer researchcancerDosage compensationaneuploidyMathematical biosciencesSystems biologyTranscription factormiRNAiScience
researchProduct

Colon Cancer Stem Cells: Promise of Targeted Therapy

2010

First developed for hematologic disorders, the concept of cancer stem cells (CSCs) was expanded to solid tumors, including colorectal cancer (CRC). The traditional model of colon carcinogenesis includes several steps that occur via mutational activation of oncogenes and inactivation of tumor suppressor genes. Intestinal epithelial cells exist for a shorter amount of time than that required to accumulate tumor-inducing genetic changes, so researchers have investigated the concept that CRC arises from the long-lived stem cells, rather than from the differentiated epithelial cells. Colon CSCs were originally identified through the expression of the CD133 glycoprotein using an antibody directed…

Cell SurvivalColonColorectal cancermedicine.medical_treatmentMetastasisTargeted therapyColon cancer stem cellsCancer stem cellBiomarkers TumormedicineAnimalsHumansHepatologybiologyCD44GastroenterologyLGR5Cell Differentiationmedicine.diseaseGene Expression Regulation NeoplasticCell Transformation NeoplasticDrug Resistance NeoplasmColonic NeoplasmsNeoplastic Stem CellsCancer researchbiology.proteinStem cellSignal TransductionAdult stem cell
researchProduct

Isolation and Culture of Colon Cancer Stem Cells

2008

Cancer stem cells (CSCs) resemble normal stem cells in several ways. Both cell types are self-renewing and when they divide, one of the daughter cells differentiates while the other retains stem cell properties, including the ability to divide in the same way again. CSCs have been demonstrated to exist in several solid tumors, including colon carcinoma; these cells are able to initiate and sustain tumor growth. There are essentially three different methods to isolate CSCs: establishment culture, the MACS (magnetic cell sorting) technology, and the FACS (fluorescence-activated cell sorting) technology.

Cell typeCell divisionColon carcinomaAntigenCancer stem cellColorectal cancermedicineBiologyCell sortingStem cellmedicine.diseaseCell biology
researchProduct

Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer

2023

Abstract Background Colorectal cancer (CRC) can be divided into four consensus molecular subtypes (CMS), each with distinct biological features. CMS4 is associated with epithelial-mesenchymal transition and stromal infiltration (Guinney et al., Nat Med 21:1350–6, 2015; Linnekamp et al., Cell Death Differ 25:616–33, 2018), whereas clinically it is characterized by lower responses to adjuvant therapy, higher incidence of metastatic spreading and hence dismal prognosis (Buikhuisen et al., Oncogenesis 9:66, 2020). Methods To understand the biology of the mesenchymal subtype and unveil specific vulnerabilities, a large CRISPR-Cas9 drop-out screen was performed on 14 subtyped CRC cell lines to un…

Cellular attachmentCancer ResearchOncologyPAK familySettore MED/50 - Scienze Tecniche Mediche ApplicateSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioEpithelial-mesenchymal transitionColorectal cancerMetastasis
researchProduct

Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses.

2014

There is epidemiological evidence that patients with certain Central Nervous System (CNS) disorders have a lower than expected probability of developing some types of Cancer. We tested here the hypothesis that this inverse comorbidity is driven by molecular processes common to CNS disorders and Cancers, and that are deregulated in opposite directions. We conducted transcriptomic meta-analyses of three CNS disorders (Alzheimer's disease, Parkinson's disease and Schizophrenia) and three Cancer types (Lung, Prostate, Colorectal) previously described with inverse comorbidities. A significant overlap was observed between the genes upregulated in CNS disorders and downregulated in Cancers, as wel…

Central Nervous SystemCancer ResearchGene ExpressionDiseaseComorbidityBioinformaticsProstate cancer0302 clinical medicineNeoplasmsGenetics (clinical)0303 health sciencesWnt signaling pathwayParkinson DiseaseAlzheimer's diseasePeptidylprolyl Isomerase[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]3. Good health[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Alzheimer's diseaseResearch ArticleSignal Transductionlcsh:QH426-470[SDV.CAN]Life Sciences [q-bio]/CancerProtein degradationBiology03 medical and health sciencesAlzheimer Disease[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]medicineGeneticsCancer GeneticsHumansGene NetworksMolecular BiologyBiologyEcology Evolution Behavior and Systematics030304 developmental biologyPeptidylprolyl isomeraseGene Expression ProfilingCancerComputational Biologymedicine.diseaseColorectal cancerComorbidityMalariaNIMA-Interacting Peptidylprolyl IsomeraseMeta-analysislcsh:GeneticsGene Expression RegulationImmunologySchizophrenia[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie030217 neurology & neurosurgery
researchProduct

Targeted Therapies for Colorectal Cancer

2015

In the last decades, the standard chemotherapeutic approach for the metastatic colorectal cancer (mCRC) treatment was represented by a 5-FU-based regimen with the addition of either oxaliplatin or irinotecan. Recent discoveries in the molecular biology field led to the spread of so-called targeted agents whose mechanism of action is based on the binding with specific target molecules (cellular receptors or soluble proteins) responsible for the activation of many transduction pathways required for malignant cell growth and survival. Among these, the most important consist of monoclonal antibodies (mAbs) and the tyrosine kinase inhibitors (TKIs). As a consequence, the different mechanism of a…

CetuximabBevacizumabbusiness.industryColorectal cancermedicine.diseaseOxaliplatinIrinotecanRegimenchemistry.chemical_compoundchemistryRegorafenibmedicineCancer researchPanitumumabHuman medicinebusinessmedicine.drug
researchProduct

Nanogel-antimiR-31 conjugates affect colon cancer cells behaviour

2017

Soft and flexible nanogels, produced by electron beam (e-beam) irradiation of poly(N-vinyl pyrrolidone) and acrylic acid, were evaluated as delivery devices of the inhibitor of miR-31, a small RNA molecule with an important role in colorectal cancer (CRC) progression. The nanogel carriers developed possess both carboxyl and primary amino groups; the former were activated to react with the primary amino group present in the purposely-functionalised AntimiR-31. Very high conjugation reaction yields were attained, as well as a remarkable colloidal and storage stability of the conjugates. The ability of these nanoconstructs to be internalized by cells and the specific interaction of conjugated …

ChemistryColorectal cancerGeneral Chemical EngineeringNanogels02 engineering and technologyGeneral ChemistryConjugated system010402 general chemistry021001 nanoscience & nanotechnologymedicine.disease01 natural sciencesIn vitro0104 chemical scienceschemistry.chemical_compoundBiochemistryBiological targetcolorectal cancer treatmentmedicineBiophysicsSettore CHIM/07 - Fondamenti Chimici Delle Tecnologie0210 nano-technologyConjugateAcrylic acidNanogel
researchProduct

2020

In spite of chemotherapy and systematic screening for people at risk, the mortality rate of colorectal cancer (CRC) remains consistently high, with 600,000 deaths per year. This low success rate in the treatment of CRC results from many failures associated with high resistance and the risk of metastasis. Therefore, in response to these therapeutic failures, new strategies have been under development for several years aimed at increasing the effect of anticancer compounds and/or at reducing their secondary effects on normal cells, thus enabling the host to better withstand chemotherapy. This study highlights that xanthohumol (Xn) concentrations under the IC50 values were able to induce apopt…

Chemotherapybusiness.industryColorectal cancerDNA damagemedicine.medical_treatmentGeneral Medicinemedicine.diseaseMetastasischemistry.chemical_compoundPrenylationchemistryApoptosisXanthohumolmedicineCancer researchbusinessDNACells
researchProduct